Article
Antibody-dependent cell-mediated cytotoxicity using T cells with NK-like phenotype in combination with avelumab, an anti-PD-L1 antibody.
Immunology - 1 Oct 2022
Liu Dong, Hu Yuefeng, Wei Jian, Zhang Wen, Piao Chunmei, Lu Yongcheng, Wang Yue, Liu Jingwei, Lu Xu
Abstract excerpt
Though the PD-L1 checkpoint inhibitor avelumab has shown efficacy in the treatment of some types of cancer, improved treatment strategies are desperately needed. We evaluated whether combined treatment with avelumab and adoptively transferred T-NK cells can provide enhanced anti-cancer effects for treating PD-L1-expressing tumours. Our results demonstrate that avelumab specifically targets tumour cells with high...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.